



# Strategy, Programmes & Partnerships

## Progress, risks & challenges

---

BOARD MEETING

**Anuradha Gupta, Deputy CEO**

22-23 June 2022, Geneva, Switzerland

Reach every child | [Gavi.org](https://gavi.org)



# Recalibration of Gavi 5.0 priorities remains relevant; some rephased activities beginning to gather momentum

Leaving no one behind with immunisation

## Recalibrated priorities

### New

- Preventing backsliding and catching up on **missed children**
- Delivering **COVID-19 vaccines** to priority populations


### Unchanged

- Reaching **zero-dose children** and missed communities
- Safeguarding **domestic financing**
- Ensuring **healthy markets** and preventing supply disruption

### Rephased

- **Vaccine Investment Strategy (VIS)** deferred
- New **vaccine introductions** paced
- **Middle Income Countries (MICs)** approach rephased

# Prolonged disruption of routine immunisation poses risk to Gavi 5.0



- **3.8% decrease** in 2021 in number vaccinated (vs 2019)
- **India** and Myanmar account for 70% of decline: signs of **strong recovery in India** in Q1 2022
- **Nigeria, DRC & Pakistan** contributing to dip in Q4 2021
- **No overall disruption** seen in **Q1 2022 for AFRO** countries reporting

Source: Monthly admin estimates, March 2022; Reflecting 34 Gavi57 countries with reporting through December 2021, accounting for 88% of the surviving infant population

# Impact of COVID-19 vaccination ramp-up yet to unfold in many countries, particularly in Africa

Proportion of children in Gavi57 countries with

more than 40% COVID-19 coverage

12 countries

**India**  
65% coverage



**Pakistan**  
55% coverage



**Half of children  
are in countries  
ramping-up COVID-19  
vaccination in 2022**

less than 40% COVID-19 coverage

45 countries



**Ethiopia**  
19% coverage




**Nigeria**  
8% coverage



**DRC**  
1% coverage

As of 8 June 2022

## Five High Impact Countries, with highly heterogeneous subnational contexts, are critical to Gavi 5.0 progress



### Progress update

#### India

Heavily impacted by pandemic and C-19 vaccination efforts; Strong progress in Q1 2022 on catching-up missed children

#### Nigeria

Good momentum on improving routine coverage and engagement on zero dose; significant challenges remain

#### DRC

Political commitment; backsliding in the last year has reversed gains; significant challenges remain

#### Pakistan

Steady RI performance though some disruption; targeted sub-national efforts with diverse partners to address inequities

#### Ethiopia

Stagnation due to on-going conflict; service restoration in safe areas; ongoing integration of RI and COVID-19 vaccination

# Many countries using integrated and innovative approaches to reach zero-dose children and missed communities



## Tailored strategies

**Djibouti:** nomadic population mapping; new delivery touchpoints (livestock sales)  
**Kyrgyzstan:** targeting urban areas and migrant communities



## Gender, Demand, CSOs

**Uganda and Tajikistan:** use of mobile vaccination services to address mothers' limited mobility



## Innovative approaches

**Afghanistan:** geospatial mapping to identify ZD children in slums and IDP camps  
**South Sudan:** pairing immunisation & veterinary services



## Leveraging campaigns

**Malawi, Tanzania, Mozambique:** polio SIAs used for ZD data and inform ZD strategy  
**Nepal:** ZD identification through Typhoid campaign



## New partnerships

**Countries across Sahel and Horn of Africa:** new partnerships to reach zero-dose children in fragile, conflict and cross-border settings outside government reach



## COVID-19 and RI Integration

**Togo:** Leveraged CDS activities to catch up missed children and ZD  
**Angola:** Planning MR vaccines with COVID-19 vaccine delivery outreaches

# Countries continuing to meet co-financing obligations; outlook is ambitious but risks remain

## Outlook

2021-2025 forecast (US\$)

Financing of  
vaccines by Gavi\*

**\$5.2bn**

Co-financing /  
self-financing  
by country

**\$3.4bn**



**For every \$1 invested by Gavi in vaccines, countries will invest \$0.65 in Gavi 5.0**

## Risks



### Need for continued advocacy:



**Government health expenditure forecast to decline** in over a quarter of countries



**Debt levels in low-income countries has increased** by 10 pp in the last two years

\* Based on 2021-2025 Financial Forecast presented to the AFC on 10 May 2022; ^ Includes self-financing by countries (inc India) of vaccines introduced with Gavi support

# Continued focus on healthy market dynamics creating more resilient, sustainable vaccine markets

## 2021 Vaccine Market Health

Acceptable

Unacceptable

COVID-19-related supply challenges mitigated; risks being monitored

Penta

CCE

Hexa

TCV

JE

MenA

Measles

MR

YF

IPV

PCV

Rota

HPV

Cholera

**PCV:** supply shocks mitigated through Alliance partner engagement; minimal programmatic impact

**Rota:** supply pressures causing at least 9 countries to switch products in 2022. Risks being monitored

**HPV:** supply constraints persist with country preferences skewed towards HPV4

**Cholera:** limited buffer capacity; low demand predictability impacting supply planning & investment



# We continue to monitor progress and risks for Gavi 5.0 closely amid on-going uncertainty

## SG1 | Introduce & scale-up vaccines

	2019	2020	2021	Assessment against target
<b>Vaccine introductions</b> # completed	25	8	13	
<b>Campaigns</b> # completed	34	11	26	

## SG3 | Improve sustainability

	2019	2020	2021	Assessment against target
<b>Co-financing fulfilment</b> % of co-financing obligations met	100%	100%	100%	
<b>Co-financing waivers</b> # approved		9	6	

## SG2 | Strengthen health systems

	2019	2020	2021	Assessment against target
<b>FPP completed</b> # completed		5	2	
<b>HSS disbursements</b> US\$	\$331m	\$383m	\$176m	
<b>TCA milestones on track</b> % of milestones on track	79%	65%	68%	

## SG4 | Ensure healthy markets

	2019	2020	2021	Assessment against target
<b>Markets with acceptable market dynamics</b> # vaccine markets		10	11	

# Gavi 5.1 | Evolution of Gavi 5.0 in light of the pandemic, and learnings from COVID-19 vaccination and COVAX



## Strategic priorities

Implications of the pandemic and COVID-19 vaccination on Gavi's strategic priorities

---

## COVID-19 vaccine programme

Design of Gavi support for a COVID-19 vaccine programme, aligned with Gavi's core programmes

---

## Pandemic response & preparedness (PPR)

Evolution of Gavi's role in PPR given the experience and new learnings from COVAX

---

## Organisational set-up and business processes

Integration of select functions and learnings from COVAX into Gavi's core operating model

# Thank you

